Recombinant Full-Length Parathyroid Hormone (1-84)

Moen, Marit D.; Scott, Lesley J
May 2007
BioDrugs;2007, Vol. 21 Issue 3, p205
Academic Journal
The article discusses the importance of recombinant full-length parathyroid hormone in treating osteoporosis. Osteoporosis occurs when the rate of bone resorption exceeds the rate of bone formation. The resulting loss of bone mass and strength can lead to fragility fractures. Available treatments for postmenopausal osteoporosis include agents that inhibit bone resorption such as bisphosphonates. Synthetic versions of endogenous parathyroid hormone have been shown to increase new bone formation.


Related Articles

  • Parathyroid Hormone in the Treatment of Osteoporosis. Fujita, T. // BioDrugs;2001, Vol. 15 Issue 11, p721 

    Parathyroid hormone (PTH), especially intact human PTH [hPTH(1-84)] and its various fragments [hPTH(1-31), (1-34), (1-36), (1-38) and their modifications], has been used for the treatment of osteoporosis over the last 10 years. Although chronic continuous excess of PTH markedly increases bone...

  • bmj updates.  // BMJ: British Medical Journal (International Edition);8/12/2006, Vol. 333 Issue 7563, preceding p311 

    The article provides a summary of the article "Parathyroid hormone for the treatment of osteoporosis: a systematic review," by A. Cranney, et al. The study evaluated the use of parathyroid hormone as a treatment for osteoporosis in women. The research found that the use of parathyroid hormone...

  • Osteoporosis and Osteonecrosis of the Jaw. Suzuki, Jon B.; Kiemes, Andrea B. // Access;Mar2008 Osteoporosis Supplement, Vol. 22, p2 

    The article offers information on osteoporosis and osteonecrosis of the jaw (ONJ), including their symptoms and treatments. Osteoporosis is a skeletal disorder characterized by compromised bone strength and can be prevented by taking drugs with bisphosphonates and parathyroid hormone. The ONJ is...

  • Parathyroid Hormone as an Anabolic Skeletal Therapy. Rubin, Mishaela R.; Bilezikian, John P. // Drugs;2005, Vol. 65 Issue 17, p2481 

    The quest for effective treatment for osteoporosis merits great attention because of the widespread prevalence of this disease, which is not only associated with fragility fractures, but also with significant morbidity and mortality. The efficacy of the antiresorptive drugs in this disease is...

  • THE EARLY BIOCHEMICAL RESPONSE OF ELDERLY PATIENTS WITH OSTEOPOROSIS TO PARATHYROID HORMONE THERAPY. Casey, M. C.; Connolly, C.; Healy, M.; Lam, M.; Maher, N.; Kirby, C.; Cunningham, C.; Coakley, D.; Walsh, J. C. // Age & Ageing;Jul2005 Supplement1, Vol. 34, pi7 

    Discusses research being done on the early biochemical response to parathyroid hormone therapy in elderly patients with osteoporosis. Reference to a study by M. C. Casey and colleagues, presented at the autumn meeting of the British Geriatrics Societies in October 2004; Biochemical markers...

  • Recombinant human parathyroid hormone. Reeve, Jonathan // BMJ: British Medical Journal (International Edition);2/23/2002, Vol. 324 Issue 7335, p435 

    Editorial. Reports that the United States Food & Drug Administration voted in favor of the recombinant parathyroid hormone for the treatment of menopausal osteoporosis. Finding that the hormone injections increase bone mass and strength; Description of how data from animal studies helped...

  • Bears, bones and osteoporosis.  // Active Living;Nov2006, Vol. 15 Issue 6, p29 

    The article discusses a review by the Scientific Advisory Council of Osteoporosis Canada which concluded that treatment with parathyroid hormone could be effective for osteoporosis. Parathyroid hormone is produced by black bears after hibernation to overcome bone loss generated by several months...

  • Parathyroid hormone (1-34) alone was better than parathyroid hormone plus alendronate in men with osteoporosis.  // ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p63 

    This article presents a study to determine whether parathyroid hormone (1-34) (PTH) plus alendronate more effective than monotherapy with either agent for increasing bone mineral density (BMD) at the lumbar spine, in men 46 to 85 years of age with osteoporosis. Increase in BMD at the lumbar...

  • Use of Recombinant Human Parathyroid Hormone(1-84) in Patients with Postmenopausal Osteoporosis.  // Clinical Drug Investigation;2011, Vol. 31 Issue 2, p87 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics